Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS

Longeveron Inc. LGVN

6 fiscal years on record · USD · FY2025 reported · SEC filings only
$1.2M
▼ 49.9% YoY
$-22.7M
$-18.9M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

USD 1.2M
Revenue, FY2025 · full 6-year series below
Revenue $M Net income $M
FY2025 · Revenue 1.2 · Net income -22.7
2M4M-10M-20M
202020232025
Compound annual growth
−0.6%
−26.6%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −26.6% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2025 · Operating -1942.2% · Net ·
-1000%-2000%
202020222025
ROE
FY2025 · ROE -164.7%
-50%-100%-150%
202020222025
Three returns, three denominators.

Each USD of equity lost 165 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -18.9
-10M-20M
202020222025

Total assetsUSD 10.3M
EquityUSD 5.7M
CashUSD 4.7M
Current ratio1.33×

Equity funds 55% of total assets.

The 6-year record

6 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
LGVN, 6-year financial record
Metric 202520242023202220212020
Revenue $B0.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0−0.0−0.0
Income tax $B0.00.00.00.0◌◌
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−1.29−2.62−10.22−0.90−0.90−0.23
Dividend / sh $◌◌◌◌◌◌
Payout % — not applicable: no dividend——————
ROE %−164.7−111.6−157.2−65.0−86.5−190.1

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 30 reconciliationsAUDITED

Reconciled in 6 of the 6 fiscal years we could check. 26 checks were skipped: the balance sheet is not tagged before 2020. 13 checks were skipped: EPS is not tagged before 2020. 13 checks were skipped: revenue is not tagged before 2020.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categoryemerging growth company
Data on record since2020

Share this section

Download image